Beyond Dopamine : Glutamate as a Target for Future Antipsychotics
Joint Authors
Sendt, Kyra-Verena
Giaroli, Giovanni
Tracy, Derek K.
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-07-05
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Pharmacy, Health & Medical Sciences
Pharmacology
Abstract EN
The dopamine hypothesis of schizophrenia remains the primary theoretical framework for the pharmacological treatment of the disorder.
Despite various lines of evidence of dopaminergic abnormalities and reasonable efficacy of current antipsychotic medication, a significant proportion of patients show suboptimal treatment responses, poor tolerability, and a subsequent lack of treatment concordance.
In recent decades, intriguing evidence for the critical involvement of other neurotransmitter systems in the pathophysiology of schizophrenia has emerged, most notably of dysfunctions within the glutamate pathways.
Consequently, the glutamate synapse has arisen as a promising target for urgently needed novel antipsychotic compounds—particularly in regards to debilitating negative and cognitive symptoms poorly controlled by currently available drugs.
In this paper, recent findings integrating glutamatergic and dopaminergic abnormalities in schizophrenia and their implications for novel pharmacological targets are discussed.
An overview of compounds in various stages of development is given: drugs enhancing NMDA receptor function as well as metabotropic glutamate receptor (mGluR) agonist and positive allosteric modulators (PAMs) are emphasised.
Together with other agents more indirectly affecting glutamatergic neurotransmission, their potential future role in the pharmacotherapy of schizophrenia is critically evaluated.
American Psychological Association (APA)
Sendt, Kyra-Verena& Giaroli, Giovanni& Tracy, Derek K.. 2012. Beyond Dopamine : Glutamate as a Target for Future Antipsychotics. ISRN Pharmacology،Vol. 2012, no. 2012, pp.1-9.
https://search.emarefa.net/detail/BIM-471362
Modern Language Association (MLA)
Sendt, Kyra-Verena…[et al.]. Beyond Dopamine : Glutamate as a Target for Future Antipsychotics. ISRN Pharmacology No. 2012 (2012), pp.1-9.
https://search.emarefa.net/detail/BIM-471362
American Medical Association (AMA)
Sendt, Kyra-Verena& Giaroli, Giovanni& Tracy, Derek K.. Beyond Dopamine : Glutamate as a Target for Future Antipsychotics. ISRN Pharmacology. 2012. Vol. 2012, no. 2012, pp.1-9.
https://search.emarefa.net/detail/BIM-471362
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-471362